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Recent evidence shows that the renin-angiotensin system is a crucial player in atherosclerotic processes. The regulation of
arterial blood pressure was considered from its ﬁrst description of the main mechanism involved. Vasoconstriction (mediated by
angiotensin II) and salt and water retention (mainly due to aldosterone) were classically considered as pivotal proatherosclerotic
activities. However, basic research and animal studies strongly support angiotensin II as a proinﬂammatory mediator, which
directlyinducesatheroscleroticplaquedevelopmentandheartremodeling.Furthermore,angiotensinIIinducesproatherosclerotic
cytokineandchemokinesecretionandincreasesendothelialdysfunction.Accordingly,thepharmacologicalinhibitionoftherenin-
angiotensin system improves prognosis of patients with cardiovascular disease even in settings of normal baseline blood pressure.
Inthepresentreview,wefocusedonangiotensin-convertingenzyme(ACE)inhibitors,angiotensinIIreceptorblockers(ARBs),and
renininhibitorstoupdatethedirectactivitiesoftherenin-angiotensinsystemininﬂammatoryprocessesgoverningatherosclerosis.
Copyright © 2009 Fabrizio Montecucco et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Atherosclerosis is a chronic inﬂammatory disease, which
involves vascular cells, immune system, and several organs
[1]. Although leukocytes, endothelial and smooth muscle
cells have been shown to play a crucial role in atherosclerotic
inﬂammation, recent evidence also supports a direct activity
for the liver, lung, heart, kidney, adipose tissue, adrenal, pan-
creatic, pituitary, and sex glands [2]. These organs produce
several soluble inﬂammatory mediators, which orchestrate
vascular and immune cell functions. Although cytokines,
chemokines as well as growth factors have been shown
to modulate inﬂammatory processes, recent studies suggest
new inﬂammatory activities for endocrine hormones [3,
4]. The renin-angiotensin system could serve an important
role in promoting inﬂammation [4, 5]. However, despite
its ﬁrst description by Tigerstedt and Bergman over a
century ago [6], the role of these hormones in inﬂammatory
processes is still unclear. The recent identiﬁcation of new
angiotensins and the diﬀerent roles of angiotensin and
renin/prorenin receptors increased the complexity of this
system, suggesting that further investigations are needed
to better understand the role of renin-angiotensin axis in
inﬂammation(Figure 1)[7–9].Furthermore,thedescription
of the angiotensin-converting enzyme (ACE) 2 and its main
product (angiotensin1–7) raised some controversies [10, 11].
ACE 2 and angiotensin1–7 levels are not inﬂuenced by ACE
inhibitors or angiotensin II receptor blockers (ARBs). On the
other hand, the “negative feed-back” regulating plasma renin
activity is modulated by these drugs [12]( Figure 2). ACE 2
and angiotensin1–7 rather appear to be upregulated by these
drugs maily in the myocardium and kidney [13, 14]. ACE 2
is also highly expressed in hypothalamus and aorta, and it is
considered as a possible modulator of the renin-angiotensin
system [15]. In particular, both ACE 2 and angiotensin1–7
may counterbalance excess of activity of the “classical”
renin-angiotensinsystem(Figure 3).AngionteninIIhasbeen
detected also in peripheral tissues (such as aortic tissue),2 Mediators of Inﬂammation
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Figure 1: Expanded renin-angiotensin-aldosteron system. Recently, the identiﬁcation of new angiotensins with diﬀerent activities increased
the complexity of this hormonal axis. In addition to the crucial activities of the liver, kidney, lung, adrenal gland cortex, and pituitary
gland, the heart also inﬂuences this system. ACE: angiotensin converting enzyme; ACE-2: angiotensin converting enzyme 2; NEP: neutral
endopaptidase; AMPA: aminopeptidase A; AMPM: aminopaptidase M.
suggesting a possible role of the local renin-angiotensin
system in atherosclerosis [16]. Both local and circulating
angiotensin II exert their activities through the binding to
angiotensin II type 1 (AT1)o rt y p e2( A T 2)r e c e p t o r s .A T 1
receptor is widely expressed on diﬀerent cell types involved
in atherosclerogenesis [17]. AT2 receptors are ubiquitously
expressedinfoetusanddramaticallyfallintheﬁrstfewhours
after birth [18]. Recently, a local renin-angiotensin system
characterized by the expression of both AT1 and AT2 recep-
torshasbeenalsoshowninadiposetissue[19].Furthermore,
the rediscovery of the “intracellular” activity of angiotensin
II as a major factor involved in cardiac remodeling suggested
new possible investigation ﬁelds [20–22]. The present review
will be focused on evidences from basic research studies and
clinical trials, investigating the role of the “revisited” renin-
angiotensin system [7] and its pharmacological inhibitions
in atherosclerotic inﬂammatory processes (Figure 2).
2.ACEInhibitors,ARBs,andReninInhibitors
inAtherosclerotic InﬂammatoryProcesses:
BasicResearch andAnimalStudies
In the last decades, basic researches have strongly suggested
that the renin-angiotensin system blockade exerts potent
antiatherosclerotic eﬀects, not only through the antihy-
pertensive pathway but also through anti-inﬂammatory,
antiproliferative, and antioxidant properties [23]. Among
these hormones, angiotensin II is considered as the main
proatherosclerotic mediator. Angiotensin II regulates not
only adhesion molecule (VCAM-1, ICAM-1, P-selectin)
expression but also cytokine, chemokine, and growth factor
secretion within the arterial wall [24]. On the other hand,
the renin-angiotensin system can modulate the activation
of complement system in both atherosclerosis and renal
injury [25–27]. This inﬂammatory cascade activates theMediators of Inﬂammation 3
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Figure 2: Simpliﬁed view of renin-angiotensin pathway and its
pharmacological inhibition. Renin inhibitors, ACE inhibitors, and
ARB modulate angiotensin activities in inﬂammatory processes.
AT1 receptors, which are expressed in immune cells, have been
shown to trigger inﬂammatory pathways.
vascular inﬂammatory response by increasing inﬂammatory
cell recruitment to intima. Recruited cells can produce
angiotensin II (intracellular angiotensin system), resulting
in a positive feedback response, which can maintain this
inﬂammatory vicious circle. In humans, an analysis of both
ruptured and hypercellular plaques demonstrated high levels
of ACE in macrophages. Accordingly, little or no ACE was
found in areas with only ﬁbrotic plaques [28, 29]. These data
suggest that ACE may be associated to atherosclerotic plaque
development and vulnerability through the direct regulation
of inﬂammatory cells. Furthermore, angiotensin II favors
the intraplaque recruitment of monocytes and lymphocytes
[30] and directly enhances TNF-α, IL-6 and cyclooxygenase-
2 expression in atherosclerotic arteries [31]. Angiotensin II-
mediated eﬀect could be potentitated by C-reactive protein
(CRP) through the upregulation of AT1 receptor expression
in vascular smooth muscle cells [32]. Angiotensin II has
been also shown to increase LDL oxidation in macrophages
[33, 34], oxLDL receptor (LOX-1) expression in endothelial
cells [35],superoxideandmetalloproteinaseproduction,and
lipid peroxidation [36]. In addition, the inactivation of nitric
oxide (NO) and prostacyclin (PGI2) has been also observed
in the presence of angiotensin II [37–40]. The binding
between angiotensin II and AT1 receptor induced proinﬂam-
matory eﬀect mainly through the down-stream activation of
intracellularsignalingcascade,whichinvolvesnuclearfactor-
kappaB (NF-κB) activation [41–43]. The activation of NF-
κB pathway increases hypertension-induced renal damage
[44]. However, Henke et al. clearly showed that, despite the
development of high blood pressure, in vivo NF-κB path-
way suppression in endothelial cells reduced hypertension-
inducedrenaldamageinmicewithendothelialcell-restricted
NF-κB superrepressor IkappaBalphaDeltaN overexpression
[45]. Accordingly, the activation of NF-κB pathways is also
crucial in atherogenesis and macrophage activation/survival
[46–48]. Therefore, angiotensin II through the activation
of NF-κB pathway could directly increase atherosclerotic
inﬂammation. The majority of the direct proinﬂammatory
eﬀects induced by angiotensin II have been shown in studies
with selective AT1 receptor blockers. Conversely, Kato et al.
showed that renin-angiotensin system-activated transgenic
mice receiving bone marrow transplantation from AT1a
knockout (KO) mice. These transgenic animals displayed
accelerated atherosclerosis and mortality [49]. The lethal
eﬀect was mainly mediated by AT1a KO macrophages that
overexpressed a number of genes involved in atherogenesis
and exhibited a greater uptake of modiﬁed lipoproteins
[49]. Given the controversial role of AT1 receptors, further
investigationsareneeded.LessisknownaboutAT2 receptors.
They are mainly localized in cardiac interstitial ﬁbroblasts
and are capable of binding not only angiotensin II but also
other angiotensins, including angiotensin III. AT2 receptors
also signal through NF-κB-mediated pathways but they may
counterbalance AT1 receptor-mediated eﬀects through the
activation of phosphatases rather than kinases [50–52]. AT2
receptor pathways increase bradykinin production and NO
synthase activity in endothelial cells [50]. AT2 receptor
activation also inhibits growth of cultured vascular smooth
muscle cells and cardiac myocytes [51, 52]. On the other
hand, the selective AT2 receptor blockade has been shown
to inhibit in vivo medial smooth muscle hypertrophy and
ﬁ b r o s i si nh y p e r t e n s i v er a t s[ 51]. These controversial results
suggest that also the role of AT2 r e c e p t o r si ss t i l ln o tc l e a r .
The renin-angiotenin system also inﬂuences inﬂammatory
mediators involved in the coagulation cascade. In particular,
this hormonal axis inhibits ﬁbrinolysis and enhances throm-
bosis by increasing plasminogen activator-1 production in
endothelial and vascular smooth muscle cells [53–55]a n db y
activating platelets [56]. The renin-angiotensin system also
stimulates platelets to release thromboxane A2 and platelet
derived growth factor [54] and increases tissue factor levels
in atherosclerotic plaques in acute coronary syndromes [57].
These basic research studies suggested that the pharmaco-
logical inhibition of the renin-angiotensin system may be
of beneﬁt against atherosclerotic inﬂammatory processes. In
fact, ACE inhibitors or ARBs do not modulate exclusively
kidney and arterial cell functions [58]. Inﬂammatory cell,
adipocyte, and cardiomyocyte functions are directly regu-
lated by these drugs [59–63]. Animal models partially con-
ﬁrmed these encouraging results. Two decades ago, the ﬁrst
preclinical studies in vivo showed that ACE inhibitors had
not only blood-pressure-lowering properties [64] but also
direct protective eﬀects on endothelium and atherogenesis
[65]. At an early stage of atherosclerosis, the treatment with
diﬀerent ACE inhibitors reduced endothelial dysfunction in
atherogenic diet-fed [66] or hyperlipidemic rabbits [67].
Quinapril reducedmacrophageinﬁltrationinatherosclerotic
lesions in femoral arteries in rabbits through the direct4 Mediators of Inﬂammation
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Figure 3: Revisited functions of the renin-angiotensin axis. Recent studies support that angiotensins inﬂuence several processes, including
inﬂammation. AT1R: angiotensin type 1 receptor; AT2R: angiotensin type 2 receptor; IRAP: insulin-regulated aminopeptidase; Mas (mas
oncogene) receptor.
inhibition of macrophage chemoattractant protein (MCP)-1
expression. Accordingly, angiotensin II itself increased MCP-
1 expression in atherosclerotic lesions, thus contributing to
macrophage inﬁltration [68]. The crucial role of the renin-
angiotensin system in inﬂammatory processes regulating
atherosclerosis was also observed in other animal models
prone to develop atherosclerosis [69–74]. In these studies,
various ACE inhibitors at doses comparable to those used
clinically reduced atherosclerotic lesions independently of
blood pressure. This was suggested by two independent
ﬁndings: (1) the use of other antihypertensive drugs did
not produce similar results [75]; (2) ACE inhibitors reduced
atherosclerosis without altering blood pressure [69]. The
beneﬁcial eﬀects of the renin-angiotensin pharmacological
inhibition have been also observed in animal models of
hypertension. The most used model was the “stroke-prone”
strain (SHR-SP) rats. Treatment with ramipril in the pre-
hypertensive phase in SHR-SP rats strongly reduced mortal-
ity and improved left-ventricular hypertrophy, cardiac and
endothelial functions, and metabolism [76]. The adminis-
tration of ACE inhibitors in the later phases of hypertension
in SHR-SP rats also decreased mortality [77], suggesting that
ACEinhibitorsreducecardiovascularriskandatherosclerosis
in animals in diﬀerent stages of cardiovascular disease. These
beneﬁts are conﬁrmed by the majority of the published
studies. However, some authors have also demonstratedMediators of Inﬂammation 5
that lowdose of trandolapril did not reduce both blood
pressure and atherosclerosis in hyperlipidemic rabbits [78].
Similarly to ACEinhibitors, ARBs reduced blood pressure
and atherosclerosis in diﬀerent animal models [79–82].
However, diﬀerently from ACE inhibitors, the protective
eﬀect of ARBs was observed at both high and lowdoses.
Although some authors did not conﬁrm ARB-mediated
beneﬁts at low doses [83], a possible dose-dependent impact
on atherogenesis, not only mediated by blood pressure
lowering, is strongly suggested. No data are available on
the use of ACE inhibitors and ARBs on atherogenesis in
transgenic rats with inducible angiotensin II (Ang II)-
dependent hypertension (TGR[Cyp1a1-Ren2]), two kidney-
one clip (2K-1C) hypertension rats, or hypertensive double
transgenic mice (R+/A+) that overexpress both human renin
(R+) and human angiotensinogen (A+). Few evidences are
available about the use of ACE inhibitors or ARBs on
mouse models with local (intracardiac) or systemic high
angiotensin II [84, 85]. However, these studies were not
focused on atherosclerosis. Therefore, further studies are
needed to clarify the role of ACE inhibitors and ARBs in
atherosclerosis in animal models with high angiotensin II
levels.InMarch2007,theUSFoodandDrudAdministration
approved a new renin-angiotensin blocker (aliskiren, a
direct renin inhibitor) for the treatment of hypertension in
humans without renal dysfunction. Renin inhibition blocks
angiotensin I generation with the consequent suppression
of angiotensin II as well as angiotensin peptide formation.
Preclinical studies strongly supported the antihypertensive
eﬃcacy and safety of aliskiren [86]. Recent evidence also
suggested a possible direct role of renin inhibitors to reduce
atherosclerotic inﬂammation [87–89]. In a double-trangenic
rat model (dTGR), overexpressing human renin and human
angiotensinogen genes, aliskiren reduced cardiac hypertro-
phy, ﬁbrosis, inﬂammation, and inducibility of arrhythmias
[90] and reversed already established cardiac and renal
damage [91]. The benicial eﬀects of renin inhibition on
organ damage are partially due to the suppression of hyper-
tension. The blockade of direct proinﬂammatory activities
of angiotensin II and angiotensin peptides represents a
crucial mechanism to reduce atherosclerosis. In fact, in
the same dTGR rat model, aliskiren and ARB losartan
also reduced albuminuria and expression of inﬂammatory
mediators, such as TNF-α, C-reactive protein (CRP) and
complement C1q, C3, C3c, and C5b-9 in comparison with
untreated controls [25]. Treatment with aliskiren has been
also shown to protect against endothelial dysfunction and
atherosclerosis in Watanabe heritable hyperlipidemic rabbits
[89]a sw e l la sA p o Ed e ﬁ c i e n t[ 87] or LDL receptor deﬁcient
[92]m i c e .
3.ACEInhibitors,ARBs, andRenin Inhibitors
inAtherosclerotic InﬂammatoryProcesses:
ClinicalTrials
At the beginning of the nineties, Dzau and Braunwald
proposed the concept of the cardiovascular continuum in
humans [103]: cardiovascular disease can be seen as a
pathophysiologic cascade induced by the presence of risk
factors, such as hypertension, hypercholesterolemia, diabetes
mellitus, and smoking. These conditions can produce well
deﬁned stages, such as endothelial dysfunction, atheroscle-
rosis, and target organ damage, followed ultimately by
the clinical syndromes (heart failure, stroke, and end-stage
renal disease) and eventually death. Experimental evidence
clearly suggests a key role of the renin-angiotensin system
and the induced inﬂammatory processes at all stages of
this continuum and consequently a strong rationale for its
blockade in order to prevent cardiovascular events [23].
The possibility of a positive eﬀect of the renin-angiotensin
blockade at the early stages of the cardiovascular contin-
uum, that is, the endothelial dysfunction, was speciﬁcally
addressed by some clinical studies. Although the complexity
of the methodology applied to these investigations did not
allow the recruitment of a very large number of patients,
the results were clearly supportive about the role of the
renin-angiotensininhibitioninthereversaloftheendothelial
dysfunction. Early evidence came from the TREND study
[104], which showed that angiotensin-converting enzyme
(ACE) inhibition with quinapril improves endothelial func-
tion of the coronary arteries. Similar results were obtained in
the coronary circulation with the ARBs: valsartan improved
basal nitric oxide production and release in hypertensive
patients as compared to diuretic-treated subjects, despite
similar blood pressure decrease [105]. The endothelial
function was evaluated also in both the peripheral [106]
and the renal circulation [107], always showing a consistent
improvement exerted by the renin-angiotensin blockade. In
addition,inasmallgroupofhypertensivepatients,resistance
arteries obtained from subcutaneous biopsies were studied
b e f o r ea n da f t e r1y e a ro ft r e a t m e n tw i t he i t h e ra nA R B
(losartan) or a β-blocker (atenolol); basal measurements
were compared to those of normotensive controls [108].
Despite similar reductions in blood pressure, losartan nor-
malized acetylcholine-dependent vasodilation and reduced
media/lumen ratio. Whereas diﬀerent ARBs exert their
eﬀects on endothelial function in a similar way (through
AT1 receptor antagonism) for ACE inhibitors we have to
consider the presence of both plasma ACE, which regulates
blood pressure, and tissue ACE, which is involved in the
regulation of tissue inﬂammation, ﬁbrosis, and hypertrophy
[109]. In BANFF study, for example, an ACE inhibitor
with low activity at the tissue level, enalapril, was not
able to aﬀect endothelial function [110]. More recently the
TRENDY study tried to compare an ARB, telmisartan, and
an ACE inhibitor, ramipril, in terms of improvement of the
renal endothelial function [107]: no signiﬁcant diﬀerences
between the two drugs were observed although the ARB
seemed to be a little more eﬃcient. The demonstration
of the prognostic signiﬁcance of endothelial dysfunction
was obtained from studies where it was possible to ﬁnd
an inverse association between the acetylcholine-stimulated
forearm blood ﬂow increase and the cumulative incidence of
cardiovascularevents[111]. Twoother surrogateparameters,
which have been evaluated in clinical studies extensively, are
the circulating inﬂammatory markers and the extension of
the vascular damage (carotid intima-media thickness [IMT],6 Mediators of Inﬂammation
Table 1: Clinical studies evaluating eﬀects of RAS blockade on circulating inﬂammatory markers. When two active drugs are administered,
the eﬀects demonstrated are with respect to basal values; when an active deug and placebo are used, the comparisons are between the two
arms. CABG: coronary artery bypass grafting; ACEI: ACE inhibitors.
Studies Patients Clinical conditions Drugs Main eﬀects
Sheth et al. [93] 107 Chronic heart failure Lisinopril versus Omapatrilat
↑ IL-10 (Omapatrilat)
= IL-6
Jilma et al. [94] 32 Essential hypertension Enalapril versus Losartan
↓ E-selectin
Enalapril ↓ ICAM-1
↓ VCAM-1
↓ MCP-1
Essential hypertension Candesartan versus Placebo
↓ MCP-1
Koh et al. [95]4 5 ↓ TNF-α
= CRP
Di Napoli and Papa [96] 507 Ischemic stroke ACEI versus Other
hypotensive drugs
↓ CRP (ACEI)
Tsikouris et al. [97]3 0 Acute myocardial infarction Quinapril versus Enalapril ↓ CRP (Quinapril)
Schieﬀer et al. [98] 48 Coronary artery disease Essential
hypertension Enalapril versus Irbesartan
↑ IL-10 Both
↓ MMP-9
↓ IL-6 Irbesartan
↓ CRP
Fliser et al. [99] 199
Essential hypertension and/or
Vascular disease Diabetes mellitus
LDL-C > 150mg/dL
Olmesartan versus Placebo
↓ CRP
↓ TNF-α
↓ IL-6
↓ MCP-1
Trevelyan et al. [100]4 5 Angina pectoris awaiting CABG Enalapril or Losartan versus
Control
↓ IL-1ra
↓ IL-6
= IL-10
= IL-8 n.d.
Tikiz et al. [101] 45 Rheumatoid arthritis Quinapril versus Placebo
= CRP
= TNF-α
= IL-1β
= IL-6
Coronary artery disease Perindopril or Enalapril
versus Placebo
↓ MCP-1 Both
Krysiak and Okopie´ n[ 102]9 0 ↑ IL-10
↓ CRP (Perindopril)
coronary circulation, and volume of the atherosclerotic
plaques). Although ACE inhibitors reduce blood levels of
inﬂammatory cytokines in vivo [102], this issue has been
addressed more in depth for ARBs [112]. Table 1 lists a series
of clinical studies, in which ACE inhibitors and ARBs reduce
serum levels of inﬂammatory markers in diﬀerent diseases
[93–102]. As for vascular structure, the less invasive way
to evaluate the possible atherosclerotic changes is the ultra-
sound determination of the carotid IMT. In the SECURE
trial, a signiﬁcant decrease in the progression slope of mean
maximal IMT by 0.04mm was observed in the active arm as
comparedtoplacebo[113].Theseresultswerenotconﬁrmed
by another study, the PART-2 trial, with the same active
drug and the same parameter [114], and also by two studies
(QUIETandSCAT)withacoronaryangiographicevaluation
[115, 116]. More recently intravascular ultrasound (IVUS)
was used in a substudy of the CAMELOT trial, which
compared the eﬀects of 3 diﬀerent treatments on atheroscle-
rosis progression: amlodipine, a calcium-antagonist, showed
no progression; enalapril, an ACE inhibitor, a trend toward
progression, which was more evident in the placebo group
[117]. Also the eﬀects of ARBs were evaluated at the vascular
levels: in a substudy of the LIFE trial, losartan, an ARB,
but not atenolol, a β-blocker, induced a regression of the
carotid artery hypertrophy in hypertensive subjects [118].
The ﬁrst successful clinical application of the experimental
observations about the role of the renin-angiotensin in the
cardiovascular pathophysiology was the demonstration of
the ACE inhibitors as an undisputed treatment in patients
with congestive heart failure or coronary artery disease
(CAD) and concomitant left ventricular dysfunction, all
clinical syndromes characterized by a strong activation
of the renin-angiotensin system [119]. These results were
subsequently conﬁrmed by trials with ARBs [120]. The ﬁrstMediators of Inﬂammation 7
studies (SAVE and SOLVD) demonstrated that these drugs
reduced both mortality rate and risk of ischemic events
[121]; moreover in SAVE the eﬀect of the ACEinhibition by
captopril was found to be independent of the degree of left
ventriculardysfunction.Thesedatasuggestedaprimaryanti-
ischemic eﬀect of the ACEinhibitors. Therefore a subsequent
step was proposed to demonstrate a signiﬁcant positive
eﬀect of the renin-angiotensin blockade in subjects at high
risk for cardiovascular events but without left ventricular
dysfunction. The HOPE study was the ﬁrst randomized
controlled trial that reached this goal: in high-risk patients
ramipril was able to induce an important 22% risk reduction
of composite cardiovascular death, MI, or stroke compared
to placebo [122]. High-risk patients were deﬁned as those
with evidence of vascular disease (CAD, stroke, peripheral
vascular disease) or diabetes plus one other cardiovascular
riskfactor(hypertension,lowhigh-densitylipoproteinlevels,
elevated total cholesterol levels, smoking, microalbumin-
uria). The analysis of the results induced intense debate
about the role of blood pressure decrease per se in the
observed beneﬁts [123]. The results in the HOPE study and
in the subsequent similar trials with other ACEinhibitors
occurred in a population of patients already receiving
standardmedicaltherapy,includingplateletinhibitors,lipid-
lowering therapy, and β-blockers. Two large trials (EUROPA
and PEACE) were performed to conﬁrm HOPE study results
with the same class of renin-angiotensin antagonists [124,
125]. The former was successful in demonstrating a similar
(20%) relative reduction of cardiovascular risk (primary
end point of cardiovascular death, MI, or cardiac arrest);
instead the latter was not able to show signiﬁcant diﬀerences
between treatment groups (ACEinhibitor versus placebo) in
the primary end point, a composite of death resulting from
cardiovascular causes, nonfatal MI, or revascularization.
Several hypotheses have been put forward to explain these
discrepancies [126]: the main reason could be the healthier
conditions of the PEACE patients with respect to the patients
enrolled in the other trials and therefore the diﬃculty for
the active treatment to demonstrate clear positive eﬀects
on the outcomes. However a meta-analysis of the three
placebo-controlled trials demonstrated a signiﬁcant eﬀect
of ACE inhibition on the occurrence of all-cause mortality,
cardiovascular mortality, nonfatal MI, stroke, heart failure,
and coronary bypass surgery [127]. The same approach
has been performed with an ARB in the TRANSCEND
study [128]. The results have shown that the active treat-
ment (telmisartan) was not superior to placebo in the
prevention of cardiovascular events, primary composite end
point represented by cardiovascular death, MI, stroke, or
admission to the hospital for heart failure events. Ripley
and Harrison suggest that these partially unexpected data
could be explained by the diﬀerences in patient number,
event rates, and the use of other life-saving drugs between
TRANSCEND and HOPE studies [129]. However these
results conﬁrm the diﬃculty to demonstrate a signiﬁcant
eﬀectoftherenin-angiotensinblockadeinthecardiovascular
prevention beyond the blood pressure control. At present,
the only suggestion of a therapeutical action which could
be independent from the changes in blood pressure levels
derives from the LIFE study [130]. In this large multicenter
trial patients with left ventricular hypertrophy were ran-
domized to receive treatment based on an ARB (losartan)
or a β-blocker (atenolol): the composite primary end point
of death, MI, and stroke was reduced by 13% with the
ARB-based treatment compared with the β-blocker-based
treatment in presence of a similar amount of blood pressure
decrease. Another important issue is the mechanism of
actionofthediﬀerentclassesofrenin-angiotensinblockers.If
angiotensin II is the key player in the inﬂammatory processes
in cardiovascular disease, we have many pharmacological
ways to inhibit its synthesis; in addition the diﬀerent classes
of drugs demonstrate other eﬀects, possibly related to a ther-
apeutic gain (so called pleiotropic actions). In fact it is well
known that ACE inhibitors are able to reduce the breakdown
of bradykinin, and this molecule can causethe most frequent
untoward eﬀects of these drugs (cough, angioedema) but it
is believed also as an important contributor to the protective
cardiovascular eﬀects exerted by them [131]. On the other
hand, ARBs signiﬁcantly increase angiotensin II levels, as a
consequence of the antagonism at the AT1 receptor site. The
possible role of the AT2 receptor stimulation in the beneﬁcial
therapeutic eﬀects of ARB remains a fascinating hypothesis
[132, 133]. These pharmacological diﬀerences could explain
the possible better results obtained with ACE inhibitors in
terms of prevention of coronary events and with ARBs in
terms of prevention of ischemic strokes [134] in comparison
with the direct competitors for renin-angiotensin blockade.
This therapeutic hypothesis has been veriﬁed by a systematic
review of the available clinical data about the two classes
of drugs [135] and by the recently published ONTARGET
trial, a very large multicenter randomized trial in which the
patients were treated with an ACE inhibitor (ramipril), an
ARB (telmisartan), or the combination of the two drugs
[136]. After a median follow-up of 56 months, the occur-
rence of the primary outcomes, consisting of death from
cardiovascularcauses,MI,stroke,orhospitalizationforheart
failure, was not signiﬁcantly diﬀerent in the ramipril and
telmisartan groups, although the ARB was better tolerated.
There were trends slightly favoring the ACE inhibitor for
MI prevention and the ARB for stroke prevention but
these diﬀerences did not reach statistical signiﬁcance. The
other issue addressed by the trial, the clinical role of the
combined renin-angiotensin blockade, brought a word of
caution about this strategy since more adverse events were
observed [137, 138]. Although in conditions of renin-
angiotensin hyperactivation, such as advanced heart failure,
and of marked proteinuria the double blockade can still
exert beneﬁcial eﬀects, other recent studies conﬁrmed the
possible risk of the combination in both a cardiological and
a nephrological setting [139–141]. In 1957, Skeggs et al.
suggested another possible approach to pharmacologically
inhibit the renin-angiotensin system [142]. Renin inhibition
was indicated as the preferred step to reduce angiotensin
II eﬀects. The discovery of prorenin receptor constitutes an
additional reason to develop a new class of renin inhibitors
[9]. An ambitious plan of primary and secondary prevention
trials has begun in order to demonstrate possible advantages
of the treatment with aliskiren alone or in combination with8 Mediators of Inﬂammation
other renin-angiotensin blockers in patients with hyperten-
sion. At present, the eﬀects independent of antihapertensive
activity of aliskiren have been shown by one clinical trials
focused on end-organ damage. In aliskiren in the evaluation
of proteinuria in diabetes (AVOID) trial, the treatment
with aliskiren reduced proteinuria independently of blood
pressure [143]. Other clinical trials have been started to
investigate the possible beneﬁts of aliskiren in cardiac
remodeling after myocardial infarction (AVANT GARDE,
ASPIRE) and diabetic nephropathy (ALTITUTE) [144].
Therefore, in the next future, further clinical evidence will
be available to conﬁrm these preliminary anti-inﬂammatory
and antiatherosclerotic eﬀects of aliskiren in humans.
4. Conclusions
The inhibition of the renin-angiotensin system represents a
pivotal approach for reducing atherosclerosis and its dra-
matic complications, such as stroke and myocardial infarc-
tion (MI). ACE inhibitors and ARBs are well-established
pharmacological tools in both primary and secondary pre-
vention of atherosclerotic cardiovascular disease. Emerging
evidence shows that their beneﬁcial eﬀects are not only due
to blood pressure lowering but also due to a direct anti-
inﬂammatory activity. Further studies are needed to better
understandthispromisinginvestigationﬁeld,withparticular
interestforthepromisingresultswiththenewrenininhibitor
treatment.
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